Ellipses Pharma: How to develop cancer drugs faster
Suzanne Wood
Next generation treatments for non-small cell lung cancer
Ellipses Pharma on our unique approach to developing cancer medicines faster
Ellipses Pharma on our unique approach to developing cancer medicines faster Hear from our Chairman, Professor Sir Chris Evans, our CEO, Dr Rajan Jethwa and our Global Head of Drug Development, Professor Tobi Arkenau alongside other industry experts and get a look inside Ellipses to discover how our unique approach develops cancer medicines faster. This [...]Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by FDA
Ellipses’ next generation selective RET inhibitor EP0031/A400 granted Fast Track designation by FDA Compound is currently undergoing clinical trials as a potential treatment option for patients with RET altered tumours. Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today that [...]Unlocking the Potential of RET-Targeted Cancer Therapies
Unlocking the Potential of RET-Targeted Cancer Therapies Simple Summary: Since the discovery of the RET gene in the early 1980s, multiple treatments have been developed that can inhibit abnormal RET signaling. The first treatments were repurposed multikinase inhibitors, however, their low selectivity for RET led to unacceptable off-target toxicities and sub-optimal exposure in patients. More [...]ODD granted by FDA
Ellipses EP0031 granted Orphan Drug Designation from the US Food and Drug Administration EP0031/A400, a next generation selective RET inhibitor (SRI), is currently being investigated as a treatment option for patients with RET altered tumours Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug [...]A Phase 1 Study of KL590586 (A400/EP0031)
A Phase 1 Study of KL590586 (A400/EP0031) - A next-generation selective RET inhibitor in patients with RET-altered solid tumours Download PDF About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to [...]EP0031 poster presented at AACR-NCI-EORTC Conference 2023
A modular, open-label, phase I/II study to evaluate the safety, tolerability, pharmacokinetics and efficacy of EP0031, a next generation selective RET inhibitor, in patients with advanced RET-altered malignancies Download larger version About Ellipses Pharma Limited Ellipses Pharma is a global drug development company based in London, focused on accelerating the development of cancer treatments through [...]Ellipses Pharma featured in The Guardian: Innovations In Oncology
Ellipses Pharma features in the Guardian Innovations In Oncology supplement By leveraging a cloud-based platform, our SAG members provide invaluable scientific and clinical insights, validate asset selection, and offer unbiased input during the drug development process using real-world evidence. This collaborative effort ensures better decision-making, faster development, and increased chances of success in bringing potential [...]Dr Vivek Subbiah talks about the Phase 1/2 trial of EP0031
Phase I/II trial of EP0031, a next generation selective RET inhibitor RET fusions occur in various cancers, and resistance to selpercatinib and pralsetinib, current first generation selective RET inhibitors that are indicated for non-small cell lung cancer and pancreatic cancer, are a growing issue. Vivek Subbiah, MD, The University of Texas MD Anderson Cancer Center, [...]